The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc is drawing attention to the estimated 1 million Americans living with drug-resistant epilepsy, particularly those who have failed to control seizures with two or more medications.
The company is promoting its RNS System as a potential solution for individuals who have not found relief through conventional drug therapies. Information about the RNS System and its safety is available through official channels, reflecting heightened efforts to address unmet needs in epilepsy management.
NeuroPace has previously encouraged patients with uncontrolled seizures to assess whether they are candidates for the RNS System through an online suitability quiz. In April, the company released findings from the NAUTILUS Study detailing advances in neuromodulation for drug-resistant idiopathic generalized epilepsy. These efforts follow continued outreach to address gaps in epilepsy care.